Vincent G. Richard's most recent trade in Forte Biosciences Inc was a trade of 31,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on March 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Forte Biosciences Inc | Richard G. Vincent | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 31,000 | 31,000 | - | - | Stock Option (right to buy) | |
| Forte Biosciences Inc | Richard G. Vincent | Director | 17 Sep 2024 | 2,000 | 2,000 | - | - | Stock Option (right to buy) | ||
| Oncternal Therapeutics Inc | G. Vincent Richard | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 14,200 | 14,200 | - | - | Stock Option | |
| Oncternal Therapeutics Inc | Vincent G. Richard | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.50 per share. | 03 Jan 2024 | 8,868 | 140,922 (0%) | 0% | 0.5 | 4,399 | Common Stock |
| Oncternal Therapeutics Inc | Richard G. Vincent | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.36 per share. | 03 Jul 2023 | 7,069 | 149,790 (0%) | 0% | 0.4 | 2,545 | Common Stock |
| Oncternal Therapeutics Inc | Richard G. Vincent | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.30 per share. | 13 Apr 2023 | 30,000 | 156,859 (1%) | 0% | 0.3 | 8,961 | Common Stock |
| Oncternal Therapeutics Inc | Richard G. Vincent | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 210,000 | 210,000 | - | - | Stock Option | |
| Oncternal Therapeutics Inc | Richard G. Vincent | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.02 per share. | 03 Jan 2023 | 4,428 | 126,859 (0%) | 0% | 1.0 | 4,517 | Common Stock |
| Oncternal Therapeutics Inc | Richard G. Vincent | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 43,125 | 131,287 (0%) | 0% | 0 | Common Stock | |
| Oncternal Therapeutics Inc | Richard G. Vincent | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2022 | 28,750 | 28,750 | - | - | Stock Option | |
| Oncternal Therapeutics Inc | Richard G. Vincent | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.40 per share. | 24 Mar 2022 | 2,500 | 88,162 (0%) | 0% | 1.4 | 3,500 | Common Stock |
| Oncternal Therapeutics Inc | Richard G. Vincent | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.49 per share. | 24 Mar 2022 | 2,136 | 85,662 (0%) | 0% | 1.5 | 3,182 | Common Stock |
| Oncternal Therapeutics Inc | Richard G. Vincent | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.45 per share. | 24 Mar 2022 | 356 | 83,521 (0%) | 0% | 1.4 | 516 | Common Stock |
| Oncternal Therapeutics Inc | Richard G. Vincent | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.40 per share. | 24 Mar 2022 | 5 | 83,526 (0%) | 0% | 1.4 | 7 | Common Stock |
| Oncternal Therapeutics Inc | Richard G. Vincent | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.33 per share. | 24 Mar 2022 | 3 | 83,165 (0%) | 0% | 1.3 | 4 | Common Stock |
| Oncternal Therapeutics Inc | Richard G. Vincent | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.70 per share. | 27 Jan 2022 | 5,000 | 80,662 (0%) | 0% | 1.7 | 8,500 | Common Stock |
| Oncternal Therapeutics Inc | Richard G. Vincent | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.80 per share. | 27 Jan 2022 | 5,000 | 75,662 (0%) | 0% | 1.8 | 9,000 | Common Stock |
| Oncternal Therapeutics Inc | Richard G. Vincent | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.65 per share. | 27 Jan 2022 | 2,500 | 83,162 (0%) | 0% | 1.7 | 4,125 | Common Stock |
| Oncternal Therapeutics Inc | Richard G. Vincent | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2022 | 109,579 | 109,579 | - | - | Stock Option | |
| Oncternal Therapeutics Inc | Richard G. Vincent | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 29,867 | 70,662 (0%) | 0% | 0 | Common Stock | |
| Oncternal Therapeutics Inc | Richard G. Vincent | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 280,000 | 280,000 | - | - | Stock Option |